Cargando…
Low-Dose Dextromethorphan for the Treatment of Fibromyalgia Pain: Results from a Longitudinal, Single-Blind, Placebo-Controlled Pilot Trial
OBJECTIVE: Fibromyalgia (FM) is a debilitating chronic pain condition with few treatment options. Central sensitization and neuroinflammation have been forwarded as models of FM pathophysiology, both of which indicate dextromethorphan (DXM) as a potential treatment. DXM is an NMDA-receptor antagonis...
Autores principales: | Mueller, Christina, Ness, Timothy J, Younger, Jarred W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851375/ https://www.ncbi.nlm.nih.gov/pubmed/33542651 http://dx.doi.org/10.2147/JPR.S285609 |
Ejemplares similares
-
Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia
por: Parkitny, Luke, et al.
Publicado: (2017) -
Effects of Naltrexone on Pain Sensitivity and Mood in Fibromyalgia: No Evidence for Endogenous Opioid Pathophysiology
por: Younger, Jarred W., et al.
Publicado: (2009) -
Abnormal immune system response in the brain of women with Fibromyalgia after experimental endotoxin challenge
por: Mueller, Christina, et al.
Publicado: (2023) -
Altered response to Toll-like receptor 4 activation in fibromyalgia: A low-dose, human experimental endotoxemia pilot study
por: Jones, Chloe, et al.
Publicado: (2023) -
A double-blinded, placebo-controlled, randomized study to evaluate the efficacy of perioperative dextromethorphan compared to placebo for the treatment of postoperative pain: a study protocol
por: Jones, Ian A., et al.
Publicado: (2023)